1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 39, 30/Sep/2021
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

COVID-19 vaccine effectiveness by product (two doses Comirnaty, Spikevax or Vaxzevria and one of Janssen), against infection ranged from 50% (95% CI: 42 to 57) for Janssen to 86% (70 to 93) for Vaxzevria-Comirnaty combination; among ≥ 60 year-olds, from 17% (−26 to 45) for Janssen to 68% (48 to 80) for Spikevax; and against hospitalisation from 74% (43 to 88) for Janssen to > 90% for other products. Two doses of vaccine were highly effective against hospitalisation, but suboptimal for infection control.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.39.2100894
2021-09-30
2024-12-21
/content/10.2807/1560-7917.ES.2021.26.39.2100894
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/39/eurosurv-26-39-1.html?itemId=/content/10.2807/1560-7917.ES.2021.26.39.2100894&mimeType=html&fmt=ahah

References

  1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15.  https://doi.org/10.1056/NEJMoa2034577  PMID: 33301246 
  2. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881-91.  https://doi.org/10.1016/S0140-6736(21)00432-3  PMID: 33617777 
  3. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16.  https://doi.org/10.1056/NEJMoa2035389  PMID: 33378609 
  4. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-201.  https://doi.org/10.1056/NEJMoa2101544  PMID: 33882225 
  5. Ministerio de Sanidad. Estrategia de detección precoz, vigilancia y control de COVID-19. [Strategy for early detection, surveillance and COVID-19 control]. Madrid: Ministerio de Sanidad; 2021. Spanish. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Estrategia_vigilancia_y_control_e_indicadores.pdf
  6. European Centre for Disease Prevention and Control (ECDC). Contact tracing: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases in the European Union –third update, 18 November 2020. Stockholm: ECDC; 2020. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-contact-tracing-public-health-management-third-update.pdf
  7. European Centre for Disease Prevention and Control (ECDC). Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK. 19 November 2020. Stockholm: ECDC; 2020. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Options-use-of-rapid-antigen-tests-for-COVID-19_0.pdf
  8. Consejo Interterritorial del Sistema Nacional de Salud. Estrategia de vacunación frente a COVID-19 en España. [Vaccination strategy against COVID-19 in Spain]. Madrid: Ministerio de Sanidad; 2021. Spanish. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_Actualizacion6_EstrategiaVacunacion.pdf
  9. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-29.  https://doi.org/10.1016/S0140-6736(21)00947-8  PMID: 33964222 
  10. Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373(1088):n1088.  https://doi.org/10.1136/bmj.n1088  PMID: 33985964 
  11. Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al. Effectiveness of Covid-19 Vaccines in ambulatory and inpatient care settings. N Engl J Med. 2021;NEJMoa2110362.  PMID: 34496194 
  12. Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Euro Surveill. 2021;26(21):2100438.  https://doi.org/10.2807/1560-7917.ES.2021.26.21.2100438  PMID: 34047271 
  13. de Gier B, Andeweg S, Joosten R, Ter Schegget R, Smorenburg N, van de Kassteele J, et al. Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021. Euro Surveill. 2021;26(31):2100640.  https://doi.org/10.2807/1560-7917.ES.2021.26.31.2100640  PMID: 34355689 
  14. Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, et al. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions - United States, March-August 2021. MMWR Morb Mortal Wkly Rep. 2021;70(38):1337-43.  https://doi.org/10.15585/mmwr.mm7038e1  PMID: 34555004 
  15. Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398(10295):121-30.  https://doi.org/10.1016/S0140-6736(21)01420-3  PMID: 34181880 
  16. Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021;27(9):1530-5.  https://doi.org/10.1038/s41591-021-01464-w  PMID: 34312554 
  17. European Centre for Disease Prevention and Control (ECDC). Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence. 22 July 2021. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Partial%20COVID%20vaccination%20and%20heterologous%20vacc%20schedule%20-%2022%20July%202021.pdf
  18. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585-94.  https://doi.org/10.1056/NEJMoa2108891  PMID: 34289274 
  19. Centers for Disease Control and Prevention (CDC). Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots. Atlanta: CDC. 18 Aug 2021. Available from: https://www.cdc.gov/media/releases/2021/s0818-covid-19-booster-shots.html
  20. European Centre for Disease Prevention and Control (ECDC). Interim public health considerations for the provision of additional COVID-19 vaccine doses, 1 September 2021. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Interim-public-health-considerations-for-the-provision-of-additional-COVID-19-vaccine-doses.pdf
  21. Lewnard JA, Patel MM, Jewell NP, Verani JR, Kobayashi M, Tenforde MW, et al. Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines. Epidemiology. 2021;32(4):508-17.  https://doi.org/10.1097/EDE.0000000000001366  PMID: 34001753 
Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Iv%C3%A1n+Mart%C3%ADnez-Baz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Martínez-Baz Iván</a>, <a href="/search?value1=Camino+Trobajo-Sanmart%C3%ADn&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Trobajo-Sanmartín Camino</a>, <a href="/search?value1=Ana+Miqueleiz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Miqueleiz Ana</a>, <a href="/search?value1=Marcela+Guevara&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Guevara Marcela</a>, <a href="/search?value1=Miguel+Fern%C3%A1ndez-Huerta&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fernández-Huerta Miguel</a>, <a href="/search?value1=Cristina+Burgui&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Burgui Cristina</a>, <a href="/search?value1=Itziar+Casado&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Casado Itziar</a>, <a href="/search?value1=Mar%C3%ADa+Eugenia+Portillo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Portillo María Eugenia</a>, <a href="/search?value1=Ana+Navascu%C3%A9s&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Navascués Ana</a>, <a href="/search?value1=Carmen+Ezpeleta&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ezpeleta Carmen</a>, <a href="/search?value1=Jes%C3%BAs+Castilla&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Castilla Jesús</a>, <a href="/search?value1=the+Working+Group+for+the+Study+of+COVID-19+in+Navarre&option1=author&noRedirect=true" class="nonDisambigAuthorLink">the Working Group for the Study of COVID-19 in Navarre</a></span>. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(39):pii=2100894. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.39.2100894" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.39.2100894</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 15 Sept 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 30 Sept 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.39.2100894
/content/10.2807/1560-7917.ES.2021.26.39.2100894
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error